Telesis Bio (TBIO) Stock Price, News & Analysis

Company Overview

Telesis Bio, Inc. develops automated synthetic biology systems designed to help researchers create and test biological molecules more efficiently. Its technology is intended to streamline the design-build-test process by automating tasks that traditionally require multiple manual laboratory steps.

The company’s primary products include the BioXp automated benchtop platforms and related consumables, software, and application-specific kits. These systems support the on-demand synthesis and assembly of DNA, messenger RNA and other biological constructs for applications such as gene and cell therapy research, vaccine development, protein engineering, diagnostics and synthetic biology.

Telesis Bio was formerly known as Codex DNA and changed its corporate name in 2023. The company markets its products to biotechnology and pharmaceutical companies, academic and government research institutions, and other life sciences organizations. Its platform is designed for use by customers in research and development laboratories in the United States and international markets.

Key Stats

• Today's Range: $0.01 to $0.01
• 50-Day Range: $0.00 to $0.04
• 52-Week Range: $0.00 to $0.15
• Volume: 100 shs
• Average Volume: 147 shs
• Market Capitalization: $18 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Telesis Bio Stock Analysis - MarketRank™

Telesis Bio scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Telesis Bio.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Telesis Bio is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Telesis Bio is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Telesis Bio has been sold short.

Short Interest Ratio / Days to Cover

Telesis Bio has a short interest ratio ("days to cover") of 0.17, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Telesis Bio has recently decreased by 53.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Telesis Bio does not currently pay a dividend.

Dividend Growth

Telesis Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.16

News Sentiment

Telesis Bio has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Telesis Bio this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Telesis Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.50% of the stock of Telesis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

37.63% of the stock of Telesis Bio is held by institutions.

Company Calendar

• Last Earnings: 11/08/2021
• Today: 10/31/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: OTCMKTS:TBIO
• Previous Symbol: NASDAQ:TBIO
• CIK: 1850079
• Web: telesisbio.com
• Phone: 858-228-4115
• Fax: N/A
• Employees: 200
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $27.51 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,800,000
• Free Float: 1,361,000
• Market Cap: $18 thousand
• Optionable: No Data
• Beta: 2.58